A randomized, double-blind, phase III study comparing biosimilar rituximab (RTXM83) plus CHOP chemotherapy versus a reference rituximab plus CHOP (R-CHOP) in patients with Diffuse Large B-Cell Lymphoma (DLBCL) given as first line
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2016
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors mAbxience
- 07 Jun 2017 Biomarkers information updated
- 22 Dec 2016 Status changed from completed to active, no longer recruiting.
- 19 May 2016 Status changed from recruiting to completed.